Transplant-Free Survival and Interventions at 6 Years in the SVR Trial.

Conference Paper

BACKGROUND: In the SVR trial (Single Ventricle Reconstruction), 1-year transplant-free survival was better for the Norwood procedure with right ventricle-to-pulmonary artery shunt (RVPAS) compared with a modified Blalock-Taussig shunt in patients with hypoplastic left heart and related syndromes. At 6 years, we compared transplant-free survival and other outcomes between the groups. METHODS: Medical history was collected annually using medical record review, telephone interviews, and the death index. The cohort included 549 patients randomized and treated in the SVR trial. RESULTS: Transplant-free survival for the RVPAS versus modified Blalock-Taussig shunt groups did not differ at 6 years (64% versus 59%, P=0.25) or with all available follow-up of 7.1±1.6 years (log-rank P=0.13). The RVPAS versus modified Blalock-Taussig shunt treatment effect had nonproportional hazards (P=0.009); the hazard ratio (HR) for death or transplant favored the RVPAS before stage II surgery (HR, 0.66; 95% confidence interval, 0.48-0.92). The effect of shunt type on death or transplant was not statistically significant between stage II to Fontan surgery (HR, 1.36; 95% confidence interval, 0.86-2.17; P=0.17) or after the Fontan procedure (HR, 0.76; 95% confidence interval, 0.33-1.74; P=0.52). By 6 years, patients with RVPAS had a higher incidence of catheter interventions (0.38 versus 0.23/patient-year, P<0.001), primarily because of more interventions between the stage II and Fontan procedures (HR, 1.72; 95% confidence interval, 1.00-3.03). Complications did not differ by shunt type; by 6 years, 1 in 5 patients had had a thrombotic event, and 1 in 6 had had seizures. CONCLUSIONS: By 6 years, the hazards of death or transplant and catheter interventions were not different between the RVPAS versus modified Blalock-Taussig shunt groups. Children assigned to the RVPAS group had 5% higher transplant-free survival, but the difference did not reach statistical significance, and they required more catheter interventions. Both treatment groups have accrued important complications. CLINICAL TRIAL REGISTRATION: URL: Unique identifier: NCT00115934.

Full Text

Duke Authors

Cited Authors

  • Newburger, JW; Sleeper, LA; Gaynor, JW; Hollenbeck-Pringle, D; Frommelt, PC; Li, JS; Mahle, WT; Williams, IA; Atz, AM; Burns, KM; Chen, S; Cnota, J; Dunbar-Masterson, C; Ghanayem, NS; Goldberg, CS; Jacobs, JP; Lewis, AB; Mital, S; Pizarro, C; Eckhauser, A; Stark, P; Ohye, RG; Pediatric Heart Network Investigators,

Published Date

  • May 22, 2018

Published In

Volume / Issue

  • 137 / 21

Start / End Page

  • 2246 - 2253

PubMed ID

  • 29437119

Pubmed Central ID

  • PMC5963989

Electronic International Standard Serial Number (EISSN)

  • 1524-4539

Digital Object Identifier (DOI)

  • 10.1161/CIRCULATIONAHA.117.029375

Conference Location

  • United States